Plus Therapeutics secures $5.7M financing

Plus Therapeutics (PSTV) has closed a private placement with aggregate initial upfront proceeds of approximately $3.7 million and received a $2.0 million advance payment from CPRIT as part of its existing $17.6 million grant award. The funding from the private placement and the CPRIT advance will support the Company’s clinical development of Rhenium Obisbemeda for leptomeningeal metastases, as well as further development of the Company’s CNSide LM diagnostic test as a pivotal trial endpoint.